Company Overview and News

24
SMC profit soars by 31%

2018-05-10 business.inquirer.net - 1
San Miguel Corp. grew its first quarter recurring net income by 31 percent to P19.4 billion.
PFP SMCP1 PF SMPFY PFP2 SMGBY SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMC2F SMC2E GSMI SMPFF

30
SMC recurring profit up 31% in 1st quarter

2018-05-10 bworldonline - 2
SAN MIGUEL CORP. (SMC) grew its consolidated recurring profit by a third in the first quarter of 2018, fueled by the performance of its liquor, beer, food, packaging, and fuel businesses.
PFP PSKXF SMCP1 PF SMPFY PFP2 SMGBY SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMC2F SMC2E PHSXY PSE GSMI SMPFF

1
Why Shaina prefers not to take an ex back

2018-05-04 entertainment.inquirer.net
After all the love battles I’ve survived, I’ve learned that it’s better to stay single than to settle—and that I can be happy even without the “ever after.” For more love lessons about this, catch Star Cinema’s “Single/Single (Love is Not Enough).”
GSMI

45
Pure Foods share sale seen to become bigger

2018-04-10 business.inquirer.net - 3
What is set to become the largest share sale in Philippine history may become even bigger after San Miguel Corp.’s chief said he could offer as much as a third of the conglomerate’s soon-to-be-consolidated food and beverage businesses to the investing public.
SMCP1 BDOUY PFP2 BDOUF SMGBF SMC MS GSMI SMPFF PFP PF SMPFY SMGBY BDO SMC2B SMC2A SMC2D SMC2C SMC2F SMC2E LTG

20
SMC share transfer deal folds food units into SMFB

2018-04-07 bworldonline
SAN Miguel Corp (SMC) said it completed the consolidation of its food businesses under San Miguel Food and Beverage Inc. (SMFB) via a transfer of shares.
SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMCP1 SMC2F SMC2E GSMI SMGBY

21
San Miguel formalizes consolidation of food and beverage business

2018-04-06 bworldonline - 1
San Miguel Corp has formalized its consolidation of its food businesses under San Miguel Food and Beverage Inc.
SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMCP1 SMC2F SMC2E GSMI SMGBY

28
Pure Foods’ name change gets SEC green light

2018-03-27 bworldonline
SAN MIGUEL Pure Foods Company, Inc. (SMPFC) said it has secured the Securities and Exchange Commission (SEC)’s approval to amend its name and primary purpose, among others, to reflect the consolidation of the San Miguel group’s traditional businesses.
PFP PSKXF SMCP1 PF SMPFY PFP2 SMGBY SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMC2F SMC2E PHSXY PSE GSMI SMPFF

8
SMPFC defers follow-on offering to 2nd half

2018-03-19 bworldonline - 4
SAN MIGUEL Pure Foods Company, Inc. (SMPFC) is pushing back a planned follow-on offering (FOO) to the second half of the year.
PFP PF SMPFY PFP2 GSMI SMPFF

1
SMC profit jumps 11%

2018-03-15 business.inquirer.net
Conglomerate San Miguel Corp. grew its recurring net profit by 11 percent to P54.7 billion last year on the back of strong earnings from its oil unit and robust traditional food and beverage businesses.
GSMI

23
SMC core profit up 11% in 2017

2018-03-15 bworldonline
SAN MIGUEL Corp. (SMC) chalked up a double-digit growth in recurring earnings last year on the back of the strong performance of its traditional businesses coupled with the positive results of its power and oil segments.
PFP SMCP1 PF SMPFY PFP2 SMGBY SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMC2F SMC2E GSMI SMPFF

20
San Miguel nets P55B

2018-03-15 business.inquirer.net
Conglomerate San Miguel Corp. grew its recurring net profit by 11 percent to P54.7 billion last year on “phenomenal” earnings from its oil business alongside robust food and beverage businesses.
SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMCP1 SMC2F SMC2E GSMI SMGBY

23
San Miguel Pure Foods earns P6.9B in 2017

2018-03-14 bworldonline
SAN MIGUEL Pure Foods Company, Inc. (SMPFC) booked a double-digit increase in earnings in 2017, boosted by the strong performance of its poultry, fresh meats, and branded business segments.
PFP SMCP1 PF SMPFY PFP2 SMGBY SMGBF SMC2B SMC2A SMC SMC2D SMC2C SMC2F SMC2E GSMI SMPFF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to PSE:GSMI / Ginebra San Miguel, Inc. on message board site Silicon Investor.

GSMI- Can it Survive??? GSMI- Can it Survive??? GSMI- Can it Survive???